Medicare and Medicaid GLP-1 Coverage in 2026: What's Actually Changing
Key Takeaways
- Medicare Part D has been legally prohibited from covering weight loss medications. That exclusion still stands as federal law
- The BALANCE Model (launched January 2026) creates a new pathway: $50/month GLP-1 access through Medicare, starting July 2026
- Only 13 state Medicaid programs currently cover GLP-1s for obesity, down from 16 in October 2025
- Insurance denials for GLP-1s run as high as 62%, but over 65% of appeals succeed
- The TREAT Obesity Act, which would permanently lift the Medicare exclusion, remains stuck in Congress
If you are on Medicare and have been trying to get coverage for Wegovy® or Zepbound® for weight loss, you already know: the system was not built for this. Federal law has prohibited Medicare Part D from covering anti-obesity medications since the program started. That rule is decades old and predates GLP-1 medications entirely.
In 2026, two parallel efforts are trying to change that. Congress is pushing the TREAT Obesity Act to remove the exclusion permanently. The executive branch took a different approach, creating the BALANCE Model to work around the exclusion using CMS Innovation Center authority. Both are live simultaneously, and neither is finished.
This guide covers the current rules, the changes underway, state-by-state Medicaid coverage, how to handle an insurance denial, and what to expect over the next 12 months.
Exploring Weight Loss Programs?
Why Medicare Does Not Cover Weight Loss Drugs
Under the Social Security Act, Medicare Part D plans are prohibited from covering drugs used for "anorexia, weight loss, or weight gain." This is not a plan-by-plan decision. It is a federal law that applies to all Part D plans. Even if a plan wanted to cover Wegovy for weight loss, it legally cannot.
What Medicare DOES cover
The exclusion is specific to the weight loss indication. The same medications may be covered under Part D when prescribed for different conditions:
- Type 2 diabetes: Ozempic® (semaglutide) and Mounjaro® (tirzepatide) are covered by most Part D plans when prescribed for diabetes
- Cardiovascular risk reduction: Wegovy received this FDA indication in March 2024. Coverage for this use is expanding
- Obstructive sleep apnea: Zepbound received this indication in December 2024. Coverage varies by plan
If you have one of these qualifying diagnoses in addition to obesity, you may be able to get coverage for the medication prescribed for that condition. The medication is the same. The covered indication is what changes.
What the Trump Administration decided
On April 4, 2025, the Trump Administration announced it would not finalize the Biden-era proposal to broadly cover anti-obesity medications under Medicare and Medicaid. The statutory exclusion remains in place as law. The BALANCE Model (see below) is the administration's alternative approach.
The BALANCE Model: Medicare's New Pathway
On December 23, 2025, CMS announced the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model. It formally launched on January 5, 2026. This is the most significant change to Medicare coverage of anti-obesity medications since the Part D program was created.
How it works
The BALANCE Model uses CMS Innovation Center authority to waive the Part D exclusion within the model. It is voluntary: manufacturers, state Medicaid agencies, and Part D plans opt in. CMS negotiates drug pricing directly with GLP-1 manufacturers, building on the White House's Most Favored Nation pricing agreements with Novo Nordisk and Eli Lilly.
The model combines medication access with evidence-based lifestyle supports (behavioral counseling, nutrition). The model goes beyond drug coverage. It is structured as a comprehensive weight management program.
What it costs beneficiaries
Medicare beneficiaries in the BALANCE Model would pay $50 per month for GLP-1 medications. Compare that to list prices of $1,000+ per month or even the manufacturer cash-pay programs at $199-$449 per month. For Medicare beneficiaries without other options, $50/month is a substantial improvement.
Who qualifies
Final eligibility criteria have not been published yet, but preliminary criteria include beneficiaries who are:
- Overweight with prediabetes
- Have had a stroke or cardiovascular disease
- Have obesity with diabetes
- Have severe obesity with uncontrolled high blood pressure
Note: this is not open to all Medicare beneficiaries with obesity. The criteria focus on those with the highest-risk comorbidities.
BALANCE Model Timeline
| Date | What Happens |
|---|---|
| Jan 5, 2026 | Model formally launched, applications open |
| Jan 8, 2026 | Application deadline for manufacturers, state Medicaid, Part D plans |
| May 2026 | State Medicaid agencies can begin joining |
| July 2026 | Medicare GLP-1 Payment Demonstration launches (bridge program) |
| Jan 2027 | Full BALANCE Model launches in Medicare Part D |
The bridge program (July 2026) operates outside the Part D benefit structure, so Part D plan sponsors carry no risk. This is designed to get medications to beneficiaries faster while the full model ramps up.
State Medicaid Coverage: A Shrinking Map
Unlike Medicare, Medicaid is administered by each state, and states can choose whether to cover anti-obesity medications. As of January 2026, 13 state Medicaid programs cover GLP-1 medications for obesity under fee-for-service. That number is down from 16 in October 2025.
The trend line is moving in the wrong direction. Four states eliminated coverage in the last quarter of 2025, driven primarily by cost. GLP-1 medications accounted for over 8% of all Medicaid prescription drug spending before rebates in 2024, up from 1% in 2019.
States that recently dropped coverage
California, New Hampshire, Pennsylvania, and South Carolina all eliminated Medicaid GLP-1 coverage for obesity after October 2025. California had been the largest Medicaid GLP-1 spender at $1.4 billion. Pennsylvania was second at approximately $298 million.
States that still cover
The 13 states that maintain coverage include Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, North Carolina, Rhode Island, Virginia, and Wisconsin (among others, per KFF data). Each state has its own eligibility criteria and prior authorization requirements.
Michigan tightened criteria significantly
Michigan is an example of coverage with heavy restrictions. As of January 1, 2026, Michigan Medicaid requires that patients be morbidly obese, have documented failure of all other weight-loss interventions, and that the medication be used specifically to avert bariatric surgery. Meeting those criteria, plus getting through prior authorization, significantly limits who actually receives coverage.
One state setting a precedent
North Dakota became the first state to mandate private insurance coverage for GLP-1/GIP medications by amending its Essential Health Benefit requirements. At least 14 states introduced legislation or took regulatory action on GLP-1 coverage in the first half of 2025. The legislative landscape is active, even as Medicaid coverage shrinks.
When Your Insurance Says No: The Appeals Process
Even with private insurance that technically covers GLP-1 medications, getting approved is not automatic. Prior authorization requirements for GLP-1s have surged from below 15% in Q3 2023 to over 80% in Q3 2024. Nearly 100% of GLP-1 prescriptions now require some form of prior authorization. Denial rates run as high as 62% depending on the plan.
The most important number: 65%
Over 65% of prior authorization appeals succeed. Nearly 40% of external reviews (independent review after internal appeal fails) overturn the original denial. The real barrier is not the appeal process itself. It's that 88% of patients never challenge their denial. They accept it and move on.
That means most of the people who would have won their appeal never tried. If you are denied, the odds favor you if you appeal.
How to appeal a GLP-1 denial
Step-by-Step Appeal Process
| Step | What to Do | Key Detail |
|---|---|---|
| 1. Understand the denial | Read the denial letter carefully | Common reasons: not medically necessary, step therapy incomplete, plan exclusion |
| 2. Gather documentation | BMI history, comorbidities, prior weight loss attempts | A physician letter of medical necessity is the strongest tool |
| 3. Internal appeal | Submit within 30-60 days (check your plan) | Include all medical records and physician letter |
| 4. Peer-to-peer review | Your doctor speaks to their reviewing physician | Often the fastest path to reversal |
| 5. External review | Independent reviewer evaluates your case | 40% overturn rate at this stage |
| 6. Alternative indication | Check if another diagnosis qualifies | CV risk reduction, diabetes, sleep apnea may be covered |
The strongest appeal strategy is a physician letter of medical necessity combined with documented prior attempts at weight loss (diet, exercise, other medications). If you have comorbidities like diabetes, cardiovascular disease, or sleep apnea, emphasize those. Some denials can be reversed by having the prescription written for a covered indication rather than weight loss specifically.
Employer Insurance Coverage Trends
If you get insurance through your employer, coverage depends entirely on your company's plan design. The trend has been rapid expansion followed by growing cost concerns.
Current coverage rates
43% of firms with 5,000+ workers cover GLP-1 medications for weight loss, up from 28% in 2024. For smaller firms (200+ workers), the rate is 19%. About 90% of larger employers who currently cover GLP-1s plan to continue, but many are adding restrictions.
What employers are changing
About half of all employers require clinical criteria beyond the FDA label. Around 38% require participation in lifestyle behavior programs as a condition of GLP-1 coverage. Some have added step therapy requirements, meaning you need to try other treatments first before the plan will approve a GLP-1.
The reason: many employers reported that use was higher than expected and that GLP-1 prescriptions significantly increased their prescription drug costs. Some are reconsidering or scaling back coverage entirely.
If your employer does not cover GLP-1s
Manufacturer savings programs are an option. NovoCare offers Wegovy at $199-$349/month for self-pay patients. LillyDirect offers Zepbound at $299-$449/month. These do not require insurance. Telehealth providers offering compounded medications (not FDA-approved) may also be an alternative at lower price points, typically $150-$600/month. See our cost breakdown by access route for details.
What to Expect in 2026-2027
The TREAT Obesity Act (Congressional path)
The TREAT Obesity Act (S.1973 / H.R.4231) would permanently remove the Part D exclusion on weight loss medications. It has bipartisan support: 82% of Republicans and 74% of Democrats favor the policy change in public polling. But the bill has been reintroduced in multiple prior Congresses and has never passed. It is currently in committee in both chambers with no hearing or vote scheduled.
The BALANCE Model (Administrative path)
The BALANCE Model is moving faster because it does not require Congressional action. The bridge program launches in July 2026, and the full model launches in January 2027. However, it is a voluntary model where manufacturers and plans opt in, eligibility is narrower than what the TREAT Act would provide, and the negotiated pricing could change.
The cost question
The CBO estimates that broadly covering anti-obesity medications under Medicare would increase net federal spending by $35 billion from 2026 to 2034. Health savings from reduced obesity-related conditions would offset less than $1 billion of that by 2034. This is the core tension: the medications work, but they are expensive at scale, and the budget math is challenging.
Whether Congress can reconcile the health benefits with the fiscal cost will determine whether the Part D exclusion is permanently lifted or whether coverage continues through narrower administrative models.
The Bottom Line
Medicare coverage for GLP-1 weight loss medications is changing, but it is not yet simple. The BALANCE Model opens a real pathway starting July 2026 at $50/month for qualifying beneficiaries, though the Part D statutory exclusion still stands as federal law. On the Medicaid side, state coverage is actually shrinking. And while private insurance covers more GLP-1 prescriptions than before, denial rates remain high and appeals are underused.
If you have been denied coverage, the data strongly suggests you should appeal. Over 65% of appeals succeed, and most patients never try. If you are on Medicare, the BALANCE Model is worth tracking as it rolls out this year. And regardless of insurance status, manufacturer programs and telehealth options provide access at prices well below list price.
Comparing Providers and Pricing?
We've researched telehealth programs that offer GLP-1 medications with transparent pricing. Compare what each program includes and costs.
Compare ProvidersFeatured Programs with Clinician Support
These programs include licensed clinician consultations and structured support. Compare what's included before deciding.
Sources
- CMS. BALANCE Model: expanding access to anti-obesity medications. January 2026.
- Congress.gov. S.1973 - TREAT Obesity Act of 2025.
- CBO. How would authorizing Medicare to cover anti-obesity medications affect the federal budget? October 2024.
- KFF. Medicaid coverage of and spending on GLP-1s. 2025.
- KFF. 2025 Employer Health Benefits Survey.
- GoodRx. Tracking insurance coverage for GLP-1 agonists. Updated 2026.
- ASPE. Medicare coverage of anti-obesity medications.
- Stateline. States retreat from covering drugs for weight loss. November 2025.